BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang J, Liang H, Hu K, Xiong Z, Cao M, Zhong Z, Yao Z, Deng M. The effects of several postoperative adjuvant therapies for hepatocellular carcinoma patients with microvascular invasion after curative resection: a systematic review and meta-analysis. Cancer Cell Int 2021;21:92. [PMID: 33549093 DOI: 10.1186/s12935-021-01790-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Sun H, Wang H, Wang Y, Zhong W, Meng Y, Lv Z, Guo W, Han B. Adjuvant transarterial chemoembolization timing after radical resection is an independent prognostic factor for patients with hepatocellular carcinoma. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1129065] [Reference Citation Analysis]
2 Yang YQ, Wen ZY, Liu XY, Ma ZH, Liu YE, Cao XY, Hou L, Xie H. Current status and prospect of treatments for recurrent hepatocellular carcinoma. World J Hepatol 2023;15:129-50. [PMID: 36926237 DOI: 10.4254/wjh.v15.i2.129] [Reference Citation Analysis]
3 Criss CR, Makary MS. Salvage locoregional therapies for recurrent hepatocellular carcinoma. World J Gastroenterol 2023; 29(3): 413-424 [PMID: 36688022 DOI: 10.3748/wjg.v29.i3.413] [Reference Citation Analysis]
4 Feng GY, Shi ZR, Zhao YF, Chen K, Tao J, Wei XF, Cheng Y. Therapeutic effect of postoperative adjuvant transcatheter arterial chemoembolization based on the neutrophil-to-lymphocyte ratio. Front Surg 2022;9:1072451. [PMID: 36684128 DOI: 10.3389/fsurg.2022.1072451] [Reference Citation Analysis]
5 Mao S, Shan Y, Yu X, Huang J, Fang J, Wang M, Fan R, Wu S, Lu C. A new prognostic model predicting hepatocellular carcinoma early recurrence in patients with microvascular invasion who received postoperative adjuvant transcatheter arterial chemoembolization. Eur J Surg Oncol 2023;49:129-36. [PMID: 36031472 DOI: 10.1016/j.ejso.2022.08.013] [Reference Citation Analysis]
6 He T, Zou J, Sun K, Yang J, Lei T, Xu L, Liu J, Yin S, Li G. Global research status and frontiers on microvascular invasion of hepatocellular carcinoma: A bibliometric and visualized analysis. Front Oncol 2022;12:1037145. [PMID: 36591459 DOI: 10.3389/fonc.2022.1037145] [Reference Citation Analysis]
7 Yang D, Zhu M, Xiong X, Su Y, Zhao F, Hu Y, Zhang G, Pei J, Ding Y. Clinical features and prognostic factors in patients with microvascular infiltration of hepatocellular carcinoma: Development and validation of a nomogram and risk stratification based on the SEER database. Front Oncol 2022;12:987603. [DOI: 10.3389/fonc.2022.987603] [Reference Citation Analysis]
8 Zheng Z, Guan R, Jianxi W, Zhao Z, Peng T, Liu C, Lin Y, Jian Z, Wu YS. Microvascular Invasion in Hepatocellular Carcinoma: A Review of Its Definition, Clinical Significance, and Comprehensive Management. Journal of Oncology 2022;2022:1-10. [DOI: 10.1155/2022/9567041] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
9 Cai J, Zhao J, Liu D, Xie H, Qi H, Ma J, Sun Z, Zhao H. Efficacy and Safety of Central Memory T Cells Combined With Adjuvant Therapy to Prevent Recurrence of Hepatocellular Carcinoma With Microvascular Invasion: A Pilot Study. Front Oncol 2021;11:781029. [PMID: 34926296 DOI: 10.3389/fonc.2021.781029] [Reference Citation Analysis]
10 Sun X, Yang Z, Mei J, Lyu N, Lai J, Chen M, Zhao M. The guiding value of microvascular invasion for treating early recurrent small hepatocellular carcinoma. Int J Hyperthermia 2021;38:931-8. [PMID: 34121576 DOI: 10.1080/02656736.2021.1937715] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]